A Phase 3 interventional study of Retatrutide and Placebo in Obesity, Overweight and Osteoarthritis, Knee, sponsored by Eli Lilly and Company. Completed at 134 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.
Among the 16 studies testing retatrutide in Obesity, this one has the largest enrollment, is one of 6 that started in 2023, is one of 9 in phase 3, and was the 5th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Hudson Biotech · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, retatrutide is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,335 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 392 across the 16 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 7th largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 51 in phase 3, and was the 32nd registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
4 of the studies testing retatrutide in Obesity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
| NCT07035093Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | 2027-09 |
| NCT07467447Hudson BiotechEffect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight | 2027-03-14 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing retatrutide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have (BMI) ≥30.0 kilograms per square meter (kg/m²), or ≥27.0 kg/m² with at least one of the following:
GOA1 Inclusion Criteria:
GSA1 Inclusion Criteria:
GZBJ Addenda (2) inclusion criteria:
Exclusion Criteria:
GOA1 exclusion criteria
GSA1 exclusion criteria
GZBJ Addenda (2) exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive retatrutide subcutaneously (SC).
Drug: Retatrutide
Participants will receive retatrutide SC.
Drug: Retatrutide
Participants will receive retatrutide SC.
Drug: Retatrutide
Participants will receive placebo.
Drug: Placebo
Participants will receive retatrutide after the placebo-controlled 80 week treatment period for an additional 24 weeks.
Drug: Retatrutide
Administered SC
Also known as: LY3437943
Administered SC
Percent Change From Baseline in Body Weight
Time frame: Baseline, Week 80
Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset
Time frame: Baseline, Week 80
Percent Change from Baseline in Body Weight in Participants in Extension Subset
Time frame: Baseline, Week 104
Percent Change from Baseline in Body Weight in Participants with Baseline BMI ≥ 35 kg/m2
Time frame: Baseline, Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 5%
Time frame: Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 10%
Time frame: Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 15%
Time frame: Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 20%
Time frame: Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 25%
Time frame: Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 30%
Time frame: Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 35%
Time frame: Baseline through Week 80
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 80
Change from Baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline, Week 80
Percent Change from Baseline in Triglycerides
Time frame: Baseline, Week 80
Percent Change from Baseline in Non-High-Density Lipoprotein (HDL)-Cholesterol
Time frame: Baseline, Week 80
Percent Change form Baseline in Fasting Insulin
Time frame: Baseline, Week 80
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Time frame: Baseline, Week 80
Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score
Time frame: Baseline, Week 80
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite-CT) Physical Function Composite Score
Time frame: Baseline, Week 80
Change from Baseline in IWQOL-Lite-CT Psychosocial Composite Score
Time frame: Baseline, Week 80
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 80
Percentage of Participants who Achieve Waist-to-Height Ratio (WHtR) <0.5
Time frame: Baseline through Week 80
Change from Baseline in HbA1c
Time frame: Baseline, Week 80
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline, Week 80
Percentage of Participants with a Change in Medication Use
Time frame: Baseline through Week 80
Percentage of Participants who Develop Type 2 Diabetes
Time frame: Baseline through Week 80
Time to Onset of Type 2 Diabetes
Time frame: Baseline through Week 80
Percent Change from Baseline in AHI for GSA1 Subset
Time frame: Baseline, Week 80
Percentage of Participants with ≥50% AHI Reduction from Baseline for GSA1 Subset
Time frame: Baseline to Week 80
Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA1 Subset
Time frame: Week 80
Percent Change from Baseline in Sleep Apnea-Specific Hypoxic Burden for GSA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form Sleep-related Impairment 8a T-score for GSA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in AHI Events Per Hour for GSA1 Subset in Participants with Baseline Body Mass Index (BMI) ≥ 35 kg/m2
Time frame: Baseline, Week 80
Percentage of Participants who Achieve AHI < 5 for GSA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in ESS Score for GSA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in Functional Outcomes of Sleep Questionnaire (FOSQ) Total Score
Time frame: Baseline to Week 80
Change from Baseline in PROMIS Sleep Disturbance Short Form 8b T-Score for GSA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in Neck Circumference for GSA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in the WOMAC Physical Function Subscale Score for GOA1 Subset
Time frame: Baseline, Week 80
Percentage of Participants who Achieve ≥ 50% Reduction in the WOMAC Pain Subscale for GOA1 Subset
Time frame: Baseline through Week 80
Percentage of Participants who Achieve ≥ 50% Reduction in the WOMAC Physical Function Subscale for GOA1 Subset
Time frame: Baseline through Week 80
Change from Baseline in the WOMAC Pain Subscale Score for GOA1 Subset with Baseline BMI ≥ 35 kg/m2
Time frame: Baseline, Week 80
Change from Baseline in the WOMAC Stiffness Subscale Score for GOA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in the WOMAC Total Score for GOA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score for GOA1 Subset
Time frame: Baseline, Week 80
Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS) Score for GOA1 Subset
Time frame: Baseline, Week 80
Percentage of Participants with an Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Function for GOA1 Subset
Time frame: Baseline through Week 80
Percentage of Participants with an Improved Categorical Shift in PGIS - Target Knee Pain for GOA1 Subset
Time frame: Baseline through Week 80
Change from Baseline in EQ-5D-5L for GOA1 Subset
Time frame: Baseline, Week 80
Percentage of Participants with a Change in Use of Allowed Concomitant Pain Medication for GOA1 Subset
Time frame: Baseline through Week 80
Change from Baseline in Joint Space Width for GOA1 Subset
Time frame: Baseline, Week 80
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)
AUC is presented as a single average measure of AUC across the study duration.
Time frame: Baseline through Week 80
Showing the first 100 of 134 sites across 12 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2023 to primary completion in Apr 2026, 32 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 32 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Retatrutide